Shares of Lupin rise on launch of Propranolol LA capsules

Lupin Pharma Canada, a fully owned subsidiary of Lupin, has released Propranolol LA (long-acting) capsules in 60 mg, 80 mg, 120 mg, and 160 mg doses in Canada. Propranolol LA is the generic version of Inderal LA, and it has been a successful therapy option for patients and healthcare practitioners since the discontinuance of Inderal LA. The introduction of Propranolol LA meets the needs of Canadian patients, underscoring Lupin’s commitment to improving healthcare access and cost. 

Following the discontinuation of Inderal LA, the development of Propranolol LA, the only extended-release version of Propranolol available to Canadian patients, has resulted in tremendous progress in meeting unmet patient requirements. This extended-release formulation not only offers constant symptom relief but also improves patient adherence and overall quality of life. 

Lupin is an innovation-led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. 

The stock P/E ratio is 51.7x, which is higher than the industry PE of 27.8x. This means that the stock is currently trading at a premium to its peers. The book value is Rs 274, which is lower than the stock price. This indicates that the stock is overvalued. The dividend yield is 0.35%, which is low. This means that investors do not expect to receive much income from dividends. The ROCE is 5.75%, which is below the industry average of 10%. This indicates that the company is not generating as much profit as its peers.  

Lupin is currently trading at Rs 1106.00, up by 8.95 points or 0.82% from its previous closing of Rs 1097.05 on the BSE. The scrip opened at Rs 1118.15 and has touched a high and low of Rs 1118.15 and Rs 1103.60 respectively. So far 4648 shares were traded on the counter. 

The BSE group ‘A’ stock of face value of Rs 2 has touched a 52-week high of Rs 1143.70 and a 52-week low of Rs 623.20. Last one week high and low of the scrip stood at Rs 1119.95 and Rs 1066.05 respectively. The current market cap of the company is Rs 49938.81 crore. The promoters holding in the company stood at 47.07%, while Institutions and Non-Institutions held 43.30% and 9.64% respectively. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet, and is subject to changes. Please consult an expert before making related decisions.